Yitao Huang

Yitao Huang

Auto-generated profile, based on publicly available information

Yitao Huang

Division of Surgical Sciences, Department of Surgery (R.T., Y.H., T.S., J.L., C.S., X.Z., J.M., K.C.K., L.-W.G.), School of Medicine, University of Virginia, Charlottesville

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Bioactive Materials
Verified
Journal Article
Open access
TSTakuro Shirasu
Takuro Shirasu
GUGo Urabe
Go Urabe
NYNisakorn Yodsanit
Nisakorn Yodsanit
YHYitao Huang
Yitao Huang
RXRuosen Xie
Ruosen Xie
LGLian-Wang Guo
Lian-Wang Guo
Open vascular reconstructions (OVR), including bypass grafts and dialysis access, are standard treatments for cardiovascular and renal diseases. Unfortunately, OVR often fail largely due to intimal hyperplasia (IH), and there are no clinical methods to prevent this complication. Perivascular drug administration during OVR presents a promising strategy for IH suppression. However, durations of drug release from carriers are generally short whereas sustained efficacy is essential for clinical success. This raises a critical question in clinical translation: can IH suppression be realistically maintained long-term (e.g., over 6 months) with short-term perivascular interventions? To address this question, we modified a rat vein-graft model to prolong IH progression. We then applied Pericelle, a nanoparticle/hydrogel hybrid system that we developed for perivascular delivery of rapamycin, an established IH-inhibitory drug. Surprisingly, despite short (∼3-month) drug release, Pericelle demonstrated IH suppression throughout 3, 6, and 9 months with IH reduced from 115.58 ± 27.89 to 40.34 ± 5.18 at 9 months (P < 0.05, n = 6 rats), as indicated by morphometric analysis. Live animal ultrasonography showed the same trend. Consistently, histone-3 lysine-27 trimethylation, an epigenetic mark associated with IH progression, was decreased at 6 months after Pericelle treatment. Moreover, Pericelle exhibited promising efficacy in mitigating IH in a porcine model of arteriovenous fistula that mimics dialysis access. These results suggest that Pericelle-mediated suppression of IH in rat vein-grafts extends much beyond drug release, offering potential solutions to longstanding translational challenges in reducing OVR failure.

29 October 2026 in Circulation Research
Verified
Journal Article
Closed access
RTRunze Tang
Runze Tang
YHYitao Huang
Yitao Huang
TSTakuro Shirasu
Takuro Shirasu
JLJing Li
Jing Li
AWAmy Webb
Amy Webb
LGLian-Wang Guo
Lian-Wang Guo
BACKGROUND: Vascular smooth muscle cell (SMC) phenotypic plasticity drives neointimal hyperplasia (IH) and contributes to atherosclerosis. Epigenetic mechanisms have been implicated in SMC plasticity, but the roles of epigenetic reader proteins are poorly understood. BAHCC1 (bromo adjacent homology domain coiled-coil 1) is a newly identified reader of the gene-repression histone mark histone-3 lysine 27 trimethylation (H3K27me3). Its role in vascular remodeling is unknown. METHODS: We investigated BAHCC1 in human restenotic and atherosclerotic arteries and in rat and mouse arterial injury models using BAHCC1 silencing, SMC-specific deletion, and an H3K27me3-binding-deficient knock-in mutation. Mechanistic studies in human aortic SMCs integrated transcriptomic and epigenomic profiling, protein-interaction assays, and single-guide RNA-dCas9-based epigenetic editing. RESULTS: BAHCC1 was upregulated in human restenotic and atherosclerotic arteries and rat arteries with IH. While BAHCC1 silenc ing reduced IH in balloon-injured rat arteries, SMC-specific BAHCC1 deletion and the H3K27me3-binding-deficient mutation (BAHCC1 Y2537A ) attenuated IH in wire-injured mouse arteries. In human SMCs, mitogen induced BAHCC1 expression through nuclear factor Y subunit-α, promoting BAHCC1-dependent dedifferentiation. Integrated transcriptomics and epigenomics identified LMO7 (LIM domain only 7), an IH suppressor, as a key BAHCC1-repressed target. BAHCC1 occupancy at LMO7 required BAHCC1-H3K27me3 interaction, and LMO7 -targeted H3K27me3 enrichment through epigenetic editing repressed its expression in a BAHCC1-dependent manner. Furthermore, BAHCC1 associated with SAP30 and RBBP4/7 to form a corepressor complex. Functionally, LMO7 silencing reversed the effects of BAHCC1 knockdown on human SMC phenotype and exacerbated IH in BAHCC1 Y2537A mice. Human genetic analyses further identified BAHCC1 variants associated with cardiovascular phenotypes and BAHCC1 expression. CONCLUSIONS: BAHCC1 is a previously unrecognized epigenetic driver of vascular remodeling. By reading H3K27me3 and recruiting corepressors to repress gene expression, BAHCC1 promotes pathological SMC phenotypic transition and IH, highlighting the BAHCC1 pathway as a potential therapeutic target for IH-associated vascular disease.